Related Experiment Video
Updated: Jun 23, 2026
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Coagulation dysfunction events associated with novel tetracycline-class drugs: a disproportionality and Bayesian
Hongxin Li1, Jun Wang2, Lingjun Kong2
1Department of Pharmacy, Liaocheng People's Hospital, Liaocheng, Shandong, China.
Frontiers in Antibiotics
|June 22, 2026
Summary
Novel tetracyclines like tigecycline and eravacycline show risk signals for coagulation dysfunction. Clinicians should monitor for these adverse drug reactions, especially in older males, to ensure patient safety.
Area of Science:
- Pharmacology
- Clinical Medicine
- Drug Safety
Background:
- Novel tetracycline-class antimicrobials are increasingly used for their favorable pharmacological profiles.
- Potential links between these drugs and coagulation dysfunction are underreported.
- This study investigates adverse event reports to identify such risks.
Purpose of the Study:
- To identify and analyze risk signals for coagulation disorders associated with three novel tetracyclines.
- To provide references for clinicians in monitoring adverse drug reactions.
- To compare reporting patterns across tigecycline, omadacycline, and eravacycline.
Main Methods:
- Utilized the FDA Adverse Event Reporting System (FAERS) database from January 2004 to December 2024.
- Employed data mining techniques including ROR, PRR, BCPNN, and MGPS.
- Analyzed 346 coagulation dysfunction reports, focusing on tigecycline, omadacycline, and eravacycline.
Main Results:
- Prominent risk signals for coagulation dysfunction were detected for tigecycline and eravacycline.
- Tigecycline exhibited the strongest signal (ROR = 46.85).
- Subgroup analyses indicated higher risks in males over 65 for tigecycline and eravacycline, and specific dosing for omadacycline, though these require cautious interpretation due to limited data.
Conclusions:
- Tigecycline and eravacycline show significant disproportionality signals for coagulation dysfunction.
- Distinct reporting patterns highlight the need for vigilance regarding novel tetracyclines.
- Clinicians should implement standardized therapeutic drug monitoring for potential coagulation abnormalities.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...